Executive Summary
Dr. Jelena Curtius, MD, MBA is an executive leader in clinical development strategy with more than 18 years of international experience supporting biotechnology and pharmaceutical organizations in advancing complex clinical development programs.
Her expertise spans clinical development strategy, global feasibility, patient engagement, operational excellence, and organizational transformation. Throughout her career, she has contributed to hundreds of global development opportunities, helping organizations make informed strategic decisions, optimize trial planning, and strengthen execution across diverse therapeutic areas.
Combining a medical background with executive leadership experience, Jelena is recognized for bringing together scientific insight, operational strategy, advanced analytics, and emerging technologies to address complex clinical development challenges. Her work focuses on enabling better decision-making, improving development efficiency, and advancing patient-centered innovation.
Beyond operational execution, Jelena is passionate about leadership, innovation, artificial intelligence, and the future of clinical research. She believes that the greatest advances in clinical development will come from integrating data, technology, and human expertise to create more effective and patient-focused development strategies.
This website serves as a platform to share insights, perspectives, and practical ideas on clinical development, leadership, innovation, and the evolving landscape of global clinical research.
Going Beyond the Spreadsheet to a 4D View of Clinical Trial Feasibility
Going Beyond the Spreadsheet to a 4D View of Clinical Trial Feasibility
By the time an enrollment curve starts to disappoint, the decision that shaped it has already been made. The study was not slow to execute—it was built around an incomplete picture of where it could realistically succeed. Most feasibility work draws that picture at the country level, identifying potential high-target geographies to pursue. But the factors that determine whether a trial works sit one layer deeper, at the
intersection of four dimensions: data, sites, patients, and what we call Precision in Practice. If any of these dimensions is overlooked, the study architecture is flawed before the first patient is ever screened. To get the full picture, sponsors need to upgrade to a 4D view of clinical trial feasibility.
At Precision for Medicine, we approach the dimensions of feasibility as moving parts ofa single living ecosystem. Thus, building a full feasibility picture is akin to assembling a puzzle, where each piece only truly makes sense when it is connected to—and put in context with—everything else.